Table 2 EGFR expression evaluated with Dako PharmDx, 31G7, 2.1E1 and SP84 using three different scoring methods; correlation between the four antibodies

DAKO

Positive

116(56.3%)

13(6.3%)*

129(62.6%)

0(0%)*

103(50%)

26(12.6%)*

Negative total

21(10.2%) 137(66.5%)

56(27.2%) 69(33.5%)

48(23.3%) 177(85.9%)

29(14.1%) 29(14.1%)

9(4.4%) 112(54.4%)

68(33%) 94(45.6%)

31G7

Positive

137(66.5%)

0(0%)*

101(49%)

36(17.5%)*

Negative total

40(19.4%) 177(85.9%)

29(14.1%) 29(14.1%)

11(5.3%) 112(54.3%)

58(28.2%) 94(45.7%)

2.1E1

Positive

112(54.3%)

65(31.6%)*

Negative total

0(0%) 112(54.3%)

29(14.1%) 94(45.7%)

DAKO

Positive

170(82.5%)

6(2.9%)*

175(85%)

1(0.4%)*

154(74.7%)

22(10.7%)*

Negative total

6(2.9%) 176(85.4%)

24(11.7%) 30(14.6%)

13(6.3%) 188(94.3%)

17(8.3%) 18(8.7%)

6(2.9%) 160(77.6%)

24(11.7%) 46(22.4%)

31G7

Positive

175(85%)

1(0.4%)*

157(76.2%)

19(9.2%) *

Negative total

13(6.3%) 188(91.3%)

17(8.3%) 18(8.7%)

3(1.5%) 160(77.7%)

27(13.1%) 46(22.3%)

2.1E1

Positive

158(76.6%)

30(14.6%)*

Negative total

2(1%) 160(77.6%)

16(7.8%) 46(22.4%)

DAKO

Positive

183(88.8%)

1(0.5%)*

183(88.8%)

1(0.5%)*

177(85.9%)

7(3.4%)*

Negative total

2(1%) 185(89.8%)

20(9.7%) 21(10.2%)

7(3.4%) 190(92.2%)

15(7.3%) 16(7.8%)

4(2.0%) 181(87.9%)

18(8.7%) 25(12.1%)

31G7

Positive

185(89.8%)

0(0%)*

178(86.4%)

7(3.4%)*

Negative total

5(2.4%) 190(92.2%)

16(7.8%) 16(7.8%)

3(1.5%) 181(87.9%)

18(8.7%) 25(12.1%)

2.1E1

Positive

179(86.9%)

11(5.3%)*

Negative total

2(1%) 181(87.9%)

14(6.8%) 25(12.1%)